Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse February 8, 2006

Director’s Report to the National Advisory Council on Drug Abuse Director’s Report to the National Advisory Council on Drug Abuse Budget Update Recent NIDA Activities What’s NIH? Science Findings

Budget Update

NIDA BUDGET (Thousands) Increase Over Prior Year AIDSAIDS TOTALTOTAL NonAIDSNonAIDS $693,282 $313, Actual $1,006, % $699,956 $300, Approp. $1,000, % 2007 PB $695,563 $299,266 $994,829 $695,563 $299,266 $994, %

What’s NIH?

First Major Independent Research Support Occurs at an Ever-Later Age For more information, see Average Age of Initial Type 1 R01/R23/R29 Award for Different Degrees Held Average Age of Initial Type 1 R01/R23/R29 Award for Different Degrees Held Fiscal Year Average age M.D.-Ph.D. M.D. Ph.D.

Pathway to Independence Award NRSA Individual and Institutional Training Awards Career Development Awards Research Project Grant Program NIH Institute and Center Practices Resources for New Investigators Research Independence For New Investigators NIH is Committed to Providing Pathways to New Investigators Program NIH Pathway to Independence Award Program Announced January 27, 2006 Opportunity for promising postdoctoral scientists to receive both mentored and independent research support from the same award Responsive to NAS 2005 Report “Bridges to Independence” Beginning in Fall 2006 NIH plans to issue 150 to 200 awards/year for the next 5 years Announced January 27, 2006 Opportunity for promising postdoctoral scientists to receive both mentored and independent research support from the same award Responsive to NAS 2005 Report “Bridges to Independence” Beginning in Fall 2006 NIH plans to issue 150 to 200 awards/year for the next 5 years

ENHANCING THE VITALITY OF THE NATIONAL INSTITUTES OF HEALTH: Organizational Change to Meet New Challenges NATIONAL ACADEMY OF SCIENCES INSTITUTE OF MEDICINE Recommendations Focused On Optimizing Function Rather Than Changing Structure Recommendations Focused On Optimizing Function Rather Than Changing Structure The NIH Office of The NIH Office of Portfolio Analysis & Portfolio Analysis & Strategic Initiatives Strategic Initiatives (OPASI) (OPASI)

Why Does NIH Need OPASI?  Need for coordinated assessment and management of the overall portfolio of NIH-funded research  Need for transparent, systematic processes for: – Coding of specific diseases and conditions – Assessing scientific opportunities and public health needs and integrating them into NIH-wide funding priorities – Coordinating funding of research areas that cut across or fall between the missions of individual Institutes and Centers  Need for coordinated assessment and management of the overall portfolio of NIH-funded research  Need for transparent, systematic processes for: – Coding of specific diseases and conditions – Assessing scientific opportunities and public health needs and integrating them into NIH-wide funding priorities – Coordinating funding of research areas that cut across or fall between the missions of individual Institutes and Centers

How Does OPASI Select and Implement Trans-NIH Research?  Proposals are reviewed by: – OPASI leadership – Institute and Center (IC) Directors – Council of Councils – Advisory Committee to the Director (ACD) – NIH Director  Once approved for funding: – Initiatives are assigned to a lead IC or ICs – Research is supported by the Common Fund  Proposals are reviewed by: – OPASI leadership – Institute and Center (IC) Directors – Council of Councils – Advisory Committee to the Director (ACD) – NIH Director  Once approved for funding: – Initiatives are assigned to a lead IC or ICs – Research is supported by the Common Fund

 Fund initiatives that are in areas of interest to multiple ICs  Current Roadmap funds will serve as the baseline for the Common Fund: 1.1% of the total NIH budget in FY 2006, growing to ~1.7% in FY 2008  Fund initiatives that are in areas of interest to multiple ICs  Current Roadmap funds will serve as the baseline for the Common Fund: 1.1% of the total NIH budget in FY 2006, growing to ~1.7% in FY 2008 Common Fund for Shared Needs  Future growth of the Common Fund:  No growth above the FY 2008 percent until the annual NIH budget increase exceeds Biomedical Research and Development Price Index (BRDPI)  Rate of growth will be determined annually by NIH Director and IC Directors  Common Fund will increase up to 5% of the total NIH budget  Future growth of the Common Fund:  No growth above the FY 2008 percent until the annual NIH budget increase exceeds Biomedical Research and Development Price Index (BRDPI)  Rate of growth will be determined annually by NIH Director and IC Directors  Common Fund will increase up to 5% of the total NIH budget

Recent NIDA Activities

NIDA Council Workgroups

NIDA Basic Science Review Workgroup NIDA Council Members Linda Porrino, Ph.D, Chair Barry Lester, Ph.D. John P. Rice, Ph.D. Linda Porrino, Ph.D, Chair Barry Lester, Ph.D. John P. Rice, Ph.D. Frank Ivy Carroll, Ph.D Yasmin Hurd, Ph.D. Guy Cabral, Ph.D. Stanley Watson, M.D., Ph.D. Marina Picciotto, Ph.D. Michael Nader, Ph.D. Kathryn Cunningham, Ph.D. Frank Ivy Carroll, Ph.D Yasmin Hurd, Ph.D. Guy Cabral, Ph.D. Stanley Watson, M.D., Ph.D. Marina Picciotto, Ph.D. Michael Nader, Ph.D. Kathryn Cunningham, Ph.D. First Meeting November 17-18, 2005 Second Meeting March 2006 First Meeting November 17-18, 2005 Second Meeting March 2006

Charge: To produce a written report that includes… NIDA Basic Science Review Workgroup Review of the current Basic Science program portfolio Recommendations to strengthen the current program Input into the 5-year plan for NIDA’s Basic Science program with an emphasis on: Genetic vulnerability and protection Epigenetics (interactions of environment and genetics) The genetics and neurobiology of social behavior Molecular biology of addiction Examination of the organization and management of DNBR and its interactions with other NIDA Divisions/Centers Review of the current Basic Science program portfolio Recommendations to strengthen the current program Input into the 5-year plan for NIDA’s Basic Science program with an emphasis on: Genetic vulnerability and protection Epigenetics (interactions of environment and genetics) The genetics and neurobiology of social behavior Molecular biology of addiction Examination of the organization and management of DNBR and its interactions with other NIDA Divisions/Centers

NIDA Council Members Constance Weisner, Dr.P.H., M.S.W., Chair David Vlahov, Ph.D. Claire E. Sterk, Ph.D. Mark Greenberg, Ph.D. Rodolfo Arredondo, Jr., Ed.D. Linda Porrino, Ph.D. Constance Weisner, Dr.P.H., M.S.W., Chair David Vlahov, Ph.D. Claire E. Sterk, Ph.D. Mark Greenberg, Ph.D. Rodolfo Arredondo, Jr., Ed.D. Linda Porrino, Ph.D. Scott Lucas, Ph.D. Kathleen Carroll, Ph.D. Tom Kosten, M.D. Scott Lucas, Ph.D. Kathleen Carroll, Ph.D. Tom Kosten, M.D. First Meeting December 6-7, 2005 Second Meeting February 7, 2006 First Meeting December 6-7, 2005 Second Meeting February 7, 2006 NIDA’s Approach to Grant-Making Work Group

Charge: To produce a written report and determine if any actions or new policies may be needed on the following… Charge: To produce a written report and determine if any actions or new policies may be needed on the following… Recommendations to ensure that in this age of restricted budgets we protect young investigators Balance between “large” versus “small” science at NIDA Guidelines regarding PI with multiple grants (NIDA or other IC) or laboratories with multiple grants Recommendations regarding length of duration of grants (R01s, Centers, program projects) Recommendations to ensure that in this age of restricted budgets we protect young investigators Balance between “large” versus “small” science at NIDA Guidelines regarding PI with multiple grants (NIDA or other IC) or laboratories with multiple grants Recommendations regarding length of duration of grants (R01s, Centers, program projects) NIDA’s Approach to Grant-Making Work Group

Social Neuroscience (RFA-DA ) (With Canadian Institutes of Health Research (CIHR)) Social Neuroscience (RFA-DA ) (With Canadian Institutes of Health Research (CIHR)) Released November 10, 2005 Application receipt Date: February 23, 2006 Released November 10, 2005 Application receipt Date: February 23, 2006

Prescription Opioid Use and Abuse in the Treatment of Pain (RFA-DA ) (with NIA and NIDCR) Prescription Opioid Use and Abuse in the Treatment of Pain (RFA-DA ) (with NIA and NIDCR) Released November 18, 2005 Application Receipt Date: February 23, 2006 Released November 18, 2005 Application Receipt Date: February 23, 2006

PAs and RFAs Issued With Other NIH Components/Agencies Foci include: Neuroimaging HIV/AIDS Biotechnology Dissemination & Implementation Research Training Foci include: Neuroimaging HIV/AIDS Biotechnology Dissemination & Implementation Research Training 29 New PAs and 11 New RFAs

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research HIV/AIDS Research

HIV/AIDS and Drug Abuse: The Complexities of Linked Epidemics HIV/AIDS and Drug Abuse: The Complexities of Linked Epidemics Press Conference & Science Meeting National Press Club November 29, 2005 Press Conference & Science Meeting National Press Club November 29, 2005

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research Special Population/ Health Disparities Special Population/ Health Disparities

National Institute on Drug Abuse Health Disparities Conference National Institute on Drug Abuse Health Disparities Conference Nearly 400 participants Plenary sessions addressed HIV/AIDS Criminal Justice Concerns Other Issues in Health Disparities Research Related to Drug Use Nearly 400 participants Plenary sessions addressed HIV/AIDS Criminal Justice Concerns Other Issues in Health Disparities Research Related to Drug Use Meeting Outcomes included: Discussion of collaborations between investigators, Established mentorship with students Increased awareness of opportunities with NIDA through grant development workshops Meeting Outcomes included: Discussion of collaborations between investigators, Established mentorship with students Increased awareness of opportunities with NIDA through grant development workshops

Administrative Supplements for Research on the Intersection of Drug Use and Criminal Justice Consequences in the African American Population Administrative Supplements for Research on the Intersection of Drug Use and Criminal Justice Consequences in the African American Population 6 Supplements Awarded Health Disparities in HIV/AIDS: Focus on African Americans (R01) (PA ) (with NIMH) Health Disparities in HIV/AIDS: Focus on African Americans (R01) (PA ) (with NIMH) Released November 10, 2005 Drug Abuse as a Cause, Correlate, or Consequence of Criminal Justice Related Health Disparities Among African Americans (R01) (PA ) Drug Abuse as a Cause, Correlate, or Consequence of Criminal Justice Related Health Disparities Among African Americans (R01) (PA ) Released November 10, 2005

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DPMCDA

Design, Synthesis and Preclinical Testing of Potential Treatment Agents for Drug Addiction (PAS ) Design, Synthesis and Preclinical Testing of Potential Treatment Agents for Drug Addiction (PAS ) Released November 9, 2005

Methylphenidate Was Associated With Significantly Better Outcomes Than Placebo Methylphenidate Was Associated With Significantly Better Outcomes Than Placebo Placebo p= Methylphenidate p= Proportion of Amphetamine Positive Urines During the 12-Week Period Source: Tiihonen, J. presented at NIDA-sponsored meeting “The Methamphetamine Menace” December 10, 2005.

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DBNBR

Epigenetics of Neurobiology and Addiction (RFA-DA ) (With Canadian Institutes Of Health Research (CIHR)) Epigenetics of Neurobiology and Addiction (RFA-DA ) (With Canadian Institutes Of Health Research (CIHR)) Released October 2, 2005 Application Receipt Date: January 23, 2006 Released October 2, 2005 Application Receipt Date: January 23, 2006

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DESPR

No year-to-year differences are statistically significant. Percent of 12th Graders Reporting Nonmedical Use of OxyContin and Vicodin in the Past Year Remained High Percent of 12th Graders Reporting Nonmedical Use of OxyContin and Vicodin in the Past Year Remained High OxyContin* Vicodin Percent Issues of Concern * Between 2002 and 2005 the abuse of OxyContin by 12 th graders increased significantly.

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research DCNBR

Developmental Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) (RFA-DA ) Developmental Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) (RFA-DA ) Released November 8, 2005 Application Receipt Date: February 23, 2006 Released November 8, 2005 Application Receipt Date: February 23, 2006

Imaging – Science Track Award for Research Transition (I/START) (R03) (PAR ) Imaging – Science Track Award for Research Transition (I/START) (R03) (PAR ) Released December 9, 2005

National Institute on Drug Abuse Special Populations Office Division of Basic Neurosciences & Behavior Research Division of Basic Neurosciences & Behavior Research Office of Extramural Affairs Office of Extramural Affairs Office of Planning & Resource Management Office of Planning & Resource Management Office of Science Policy & Communications Office of Science Policy & Communications Intramural Research Program Intramural Research Program Division of Epidemiology, Services & Prevention Research Division of Epidemiology, Services & Prevention Research Division of Pharmacotherapies & Medical Consequences of Drug Abuse Division of Pharmacotherapies & Medical Consequences of Drug Abuse Center for the Clinical Trials Network Center for the Clinical Trials Network Teresa Levitin, PhD Laura Rosenthal Timothy Condon, PhD Betty Tai, PhD David Shurtleff, PhD Frank Vocci, PhD Wilson Compton, MD, MPE Barry Hoffer, MD, PhD Office of the Director Nora D. Volkow, MD Director Timothy P. Condon, Ph.D. Deputy Director Laura S. Rosenthal Associate Director for Management Associate Director for Management Division of Clinical Neuroscience & Behavioral Research Division of Clinical Neuroscience & Behavioral Research Joseph Frascella, PhD Director, AIDS Research CCTN

1. Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone and methadone on liver function 10 sites, April Prescription Opioid Addiction Treatment Study (POATS) ~ 12 sites, Spring Randomized Controlled Trial of Methylphenidate in Adolescents with ADHD and Substance Use Disorders 10 sites, February Methylphenidate in Maintaining Abstinence in Smokers with ADHD 6 sites, 255 pre-screened; 52 consented; 16 randomized 5.Protocol to assess the utility of 12-Step Facilitation in increasing 12-Step participation and improving drug abuse treatment outcomes (in cocaine and meth abusers) under development 1. Starting Treatment with Agonist Replacement Therapies (START): compare the effect of buprenorphine/naloxone and methadone on liver function 10 sites, April Prescription Opioid Addiction Treatment Study (POATS) ~ 12 sites, Spring Randomized Controlled Trial of Methylphenidate in Adolescents with ADHD and Substance Use Disorders 10 sites, February Methylphenidate in Maintaining Abstinence in Smokers with ADHD 6 sites, 255 pre-screened; 52 consented; 16 randomized 5.Protocol to assess the utility of 12-Step Facilitation in increasing 12-Step participation and improving drug abuse treatment outcomes (in cocaine and meth abusers) under development Update on New CTN Protocols

Update on NIH & NIDA Initiatives

NIH Roadmap ACCELERATING MEDICAL DISCOVERY TO IMPROVE HEALTH NIH Roadmap Activities

Primary Recommendations: Improve public relations for the Molecular Library/Molecular Imaging (ML/MI) Program Provide incentives for participation in the initiatives Primary Recommendations: Improve public relations for the Molecular Library/Molecular Imaging (ML/MI) Program Provide incentives for participation in the initiatives Exploring NIDA’s Opportunities in the NIH Roadmap Molecular Libraries Project Exploring NIDA’s Opportunities in the NIH Roadmap Molecular Libraries Project October 18 and 19, 2005

Integration of Clinical Research Networks Clinical Research Training and Career Development Harmonization of Clinical Research Policy Institutional Clinical and Translation Science Awards Interdisciplinary Research (within the Roadmap theme: Research Teams of the Future) Integration of Clinical Research Networks Clinical Research Training and Career Development Harmonization of Clinical Research Policy Institutional Clinical and Translation Science Awards Interdisciplinary Research (within the Roadmap theme: Research Teams of the Future)

for Neuroscience Research Neuroscience Information Framework Laboratory of Neuroinformatics Weill Medical College of Cornell University SOCIETY FOR NEUROSCIENCE LNI PI -- Daniel Gardner NIH Goal: To develop a comprehensive, dynamic inventory of Web-accessible neuroscience information resources that span multiple levels of biological function NIH Goal: To develop a comprehensive, dynamic inventory of Web-accessible neuroscience information resources that span multiple levels of biological function Five Groups – at Caltech, Cornell, UCSD, George Mason, and Yale– have partnered with the SfN and with volunteer collaborators at nine additional sites to develop: The Framework Terminology/Ontology for neuroscience A content-based query tool Five Groups – at Caltech, Cornell, UCSD, George Mason, and Yale– have partnered with the SfN and with volunteer collaborators at nine additional sites to develop: The Framework Terminology/Ontology for neuroscience A content-based query tool Phase I began September 30, 2005

RFAs Neuroscience Blueprint Interdisciplinary Center Core Grants (RFA-NS ) -- Issued: September 29, 2005; Application Receipt Date: January 19, 2006 Development of Recombinase-Expressing (“Driver”) Mouse Lines for Studying the Nervous System (U01) (RFA-MH ) Issued November 18, 2005; Application Receipt Date: January 19, 2006 Training in Translational Research in Neurobiology of Disease (T32) (RFA-DA ) -- Issued November 9, 2005; Application Receipt Date: February 22, 2006 Training in Computational Neuroscience: From Biology to Model and Back Again (T90) (RFA-DA ) Issued: December 16, 2005; Application Receipt Date: March 13, 2006 Training in Neuroimaging: Integrating First Principles and Applications (T90) (RFA-DA ) Issued December 23, 2005; Application Receipt Date: March 13, 2006 Neuroscience Blueprint Interdisciplinary Center Core Grants (RFA-NS ) -- Issued: September 29, 2005; Application Receipt Date: January 19, 2006 Development of Recombinase-Expressing (“Driver”) Mouse Lines for Studying the Nervous System (U01) (RFA-MH ) Issued November 18, 2005; Application Receipt Date: January 19, 2006 Training in Translational Research in Neurobiology of Disease (T32) (RFA-DA ) -- Issued November 9, 2005; Application Receipt Date: February 22, 2006 Training in Computational Neuroscience: From Biology to Model and Back Again (T90) (RFA-DA ) Issued: December 16, 2005; Application Receipt Date: March 13, 2006 Training in Neuroimaging: Integrating First Principles and Applications (T90) (RFA-DA ) Issued December 23, 2005; Application Receipt Date: March 13, 2006 for Neuroscience Research

Primary Care Physicians Are Often Reluctant To Treat Substance Abuse or Fail to Link This With Their Patients’ Other Medical Conditions Primary Care Physicians Are Often Reluctant To Treat Substance Abuse or Fail to Link This With Their Patients’ Other Medical Conditions Mental Illness Cancer Infectious Diseases (HIV, HCV) Cardiac Pulmonary Learning Disorders Obesity Cerebrovascular (strokes) Trauma (accidents) Mental Illness Cancer Infectious Diseases (HIV, HCV) Cardiac Pulmonary Learning Disorders Obesity Cerebrovascular (strokes) Trauma (accidents)

NIDA’s Primary Care Outreach Initiative Physician Work Group Established to help us craft our activities in this area Workgroup Meeting Held January 27, 2006 Physicians’ Page Added to our Website Physician Work Group Established to help us craft our activities in this area Workgroup Meeting Held January 27, 2006 Physicians’ Page Added to our Website

Opportunities for Collaboration and NATIONAL INSTITUTE ON DRUG ABUSE NIDA Create an Interagency Workgroup between FDA and NIDA Re-establish a body of drug abuse expertise similar to the former FDA Drug Abuse Advisory Council (DAAC) chartered from Create an Interagency Workgroup between FDA and NIDA Re-establish a body of drug abuse expertise similar to the former FDA Drug Abuse Advisory Council (DAAC) chartered from

Recent Meetings, Conferences and Events Recent Meetings, Conferences and Events

Addiction and Obesity – Brain Systems Commonalities Presentation by the Jacob A. Waletzky Award Recipient Neurobiological Basis for Co-occurring Substance Abuse & Mental Illness Poster Session: Early Career Investigators mGluR: A Substrate in the Neurobiology of Addiction Reconsolidation of Memory: A New Approach to Treat Drug Addiction? Adolescent Drug Abuse: Brain Development, Cognition & Vulnerability Addiction and Obesity – Brain Systems Commonalities Presentation by the Jacob A. Waletzky Award Recipient Neurobiological Basis for Co-occurring Substance Abuse & Mental Illness Poster Session: Early Career Investigators mGluR: A Substrate in the Neurobiology of Addiction Reconsolidation of Memory: A New Approach to Treat Drug Addiction? Adolescent Drug Abuse: Brain Development, Cognition & Vulnerability November 11, :00AM to 9:00PM

Congressional Meth Caucus Roundtable September 25, Sponsored by members of the Congressional Caucus to Fight and Control Methamphetamine HIV/AIDS & Drug Abuse Hill Briefing October 25, Sponsored by the Friends of NIDA and the Chairs of the Congressional Addiction Treatment & Recovery Caucus Congressional Meth Caucus Roundtable September 25, Sponsored by members of the Congressional Caucus to Fight and Control Methamphetamine HIV/AIDS & Drug Abuse Hill Briefing October 25, Sponsored by the Friends of NIDA and the Chairs of the Congressional Addiction Treatment & Recovery Caucus Congressional Briefings, Hearings & Events Methamphetamine Hearing November 17, 2005 – Sponsored by the House Education and the Workforce Subcommittee on Education Reform Methamphetamine Hearing November 17, 2005 – Sponsored by the House Education and the Workforce Subcommittee on Education Reform U.S. Senators’ National Town Hall on Methamphetamine Awareness & Prevention January 23, 2006 – Sponsored by Senators Colman, Burns, Baucus, Pryor and Hagel U.S. Senators’ National Town Hall on Methamphetamine Awareness & Prevention January 23, 2006 – Sponsored by Senators Colman, Burns, Baucus, Pryor and Hagel

Science Findings

Source: Monitoring the Future Study, 2005 Cigarettes: Trends in Thirty-Day Prevalence of Use for Twelfth Graders Cigarettes: Trends in Thirty-Day Prevalence of Use for Twelfth Graders

Smoking Rate ( Cigarettes/day) Plasma Cotinine (ng/ml) Plasma 3-HC: Cotinine Ratio Plasma Cotinine: CPD Ratio p=.013 p=.026 p=.033 Caucasian African American African American African American African American African American African American African American African American Source: Moolchan, E.T et al., Ethnicity and Disease, Adolescent Nicotine Metabolism: Ethnoracial Differences Among Dependent Smokers Adolescent Nicotine Metabolism: Ethnoracial Differences Among Dependent Smokers

MALDI-IM-oTOF Mass Spectrometer The instrument was developed through two DBNBR contracts with Ionwerks (J. Albert Schultz, PI) The instrument was developed through two DBNBR contracts with Ionwerks (J. Albert Schultz, PI) A custom built mass spectrometer equipped with an ion mobility cell has been established in the laboratory of Dr. Amina Woods, NIDA IRP A custom built mass spectrometer equipped with an ion mobility cell has been established in the laboratory of Dr. Amina Woods, NIDA IRP

R 2 = % 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Established Investigator New Investigator Percentage of New Investigators in Competing R01 Awards Continues to Decrease FY FY 2003

Stakeholders EvaluationIC Directors Scientific Analysis/ Burden of Illness Data OD Programmatic Offices Council of Councils IC Directors NIH Director Advisory Committee to the Director OPASI Approval to Fund Initiative Regular Roadmap-like Process The external community has a voice in proposing AND choosing OPASI initiatives

Bupropion Reduced Methamphetamine-Induced Subjective Effects and Cue-Induced Craving Bupropion Reduced Methamphetamine-Induced Subjective Effects and Cue-Induced Craving Source: Newton, TF et al., Neuropsychopharmacology Advance online publication November 23, 2005.

Reward Neurocircuitry in Adolescent Development and Decision Making Reward Neurocircuitry in Adolescent Development and Decision Making January 20, 2006 Sponsored By: NIDA, NIMH, NICHD and NINDS January 20, 2006 Sponsored By: NIDA, NIMH, NICHD and NINDS

To Revitalize their Involvement We Need to Increase Awareness of Drug Abuse and Addiction Issues Among Primary Care Physicians To Revitalize their Involvement We Need to Increase Awareness of Drug Abuse and Addiction Issues Among Primary Care Physicians